Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment

OBJECTIVE: We previously reported that 2 years of costimulation modulation with abatacept slowed decline of β-cell function in recent-onset type 1 diabetes (T1D). Subsequently, abatacept was discontinued and subjects were followed to determine whether there was persistence of effect. RESEARCH DESIGN...

Full description

Saved in:
Bibliographic Details
Main Authors: Orban, Tihamer, Bundy, Brian, Becker, Dorothy J., DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Greenbaum, Carla J., Marks, Jennifer B., Monzavi, Roshanak, Moran, Antoinette, Peakman, Mark, Raskin, Philip, Russell, William E., Schatz, Desmond, Wherrett, Diane K., Wilson, Darrell M., Krischer, Jeffrey P., Skyler, Jay S.
Format: Artigo
Language:Inglês
Published: American Diabetes Association 2014
Subjects:
Emerging Technologies and Therapeutics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3964491/
https://ncbi.nlm.nih.gov/pubmed/24296850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc13-0604
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items